US 11769597
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
granted A61PA61P27/02
Quick answer
US patent 11769597 (Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Sep 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 20
- CPC classes
- A61P, A61P27/02